FDA approves Novo Nordisk’s oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes
On Oct. 17, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Rybelsus®, the only oral GLP-1…
-
-
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
On Oct. 9, 2025, Celltrion announced announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar…
-
Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
On Sept. 30, 2025, Zoetis announced that Dectomax®-CA1 Injectable is the first and only parasite control product to…
-
Merck to scrap London drug research centre
On Sept. 10, 2025, Merck announced it was scrapping research operations in London, citing the UK’s challenging business…
-
Johnson & Johnson to Invest $2 Billion at State-Of-The-Art North Carolina Facility
On Aug. 21, 2025, Johnson & Johnson announced it will increase its presence in North Carolina with a…
-
Biotechnology | Disease | FDA | Therapeutics
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B
On Jul. 31, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved Alhemo® (concizumab-mtci)…
-
Biotechnology | CMO | Medical Device | Medicine | Pharmaceutical | Vaccine
Simtra BioPharma Solutions Announces Strategic Purchase to Expand U.S. Manufacturing Capacity for Injectable Medicines
On Jul. 25, 2025, Simtra BioPharma announced the purchase from Cook Group of a 65-acre property (301 N….
-
geneticists are rewriting the narrative of Neanderthals and other ancient humans
On Jul. 12, 2025, an international team of geneticists and AI experts are adding whole new chapters to…
-
Biotechnology | Disease | FDA | Therapeutics
Merck spends $10 billion for Verona, gaining access to its COPD medication
On Jul. 9, 2025, pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases,…
-
Major autism study uncovers biologically distinct subtypes, paving the way for precision diagnosis and care
On Jul. 9, 2025, researchers at Princeton University and the Simons Foundation have identified four clinically and biologically…
-
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
On Jul. 7, 2025, Celltrion announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab)…
-
Hikma Pharmaceuticals announces $1 Billion investment in U.S. Expansion
On Jun. 28, 2025, Hikma Pharmaceuticals USA announced it will invest $1 billion by 2030 to further expand…
-
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults overweight or obesity in REDEFINE 1, published in NEJM
On Jun. 22, 2025, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3…
-
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention RSV Lower Respiratory Tract Disease in Infants
On Jun. 9, 2025, Merck announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for…
-
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
On May 30, 2025, Pfizer announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER…
-
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening U.S. presence
On May 22, 2025, Sanofi announces the formal opening of the company’s new flagship U.S. offices, unveiling a…
-
Disease | FDA | Neurology | Pharmaceutical | Therapeutics
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for Acute Treatment of Migraine
On May 15, 2025, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya®…
-
Sanofi to invest $20 billion in U.S. through 2030
On Mar. 14, 2025, Sanofi announced that it plans to invest at least $20 billion in the United…
-
Merck Breaks Ground on $1 Billion Biologics Center in Wilmington
On Apr. 29, 2025, Merck announced the start of construction for a $1 billion, 470,000 square-foot state-of-the-art biologics…
-
Roche to invest $50 billion in pharmaceuticals and diagnostics in the U.S. over the next five years
On Apr. 22, 2025, Roche announced that it will invest USD $50 billion into the United States in…
-
Roche to invest USD $50 billion in pharmaceuticals and diagnostics in the U.S. over the next five years
On Apr. 21, 2025, Roche announced that it will invest USD 50 billion into the United States in…
-
Novartis to expand US-based manufacturing and R&D footprint with investment of $23B over the next 5 years
On Apr. 10, 2025, Novartis, a leading global innovative medicines company, announced a planned $23 billion investment over…
-
Scientists complete largest wiring diagram and functional map of the brain to date
On Apr. 9, 2025, a team of neuro scientists scientists published findings from the Machine Intelligence from Cortical…
-
Merck buys rights to heart disease drug in latest China deal worth up to $2 billion
On Mar. 25, 2025, Merck announced it has signed a licensing agreement for a heart disease drug with…
-
Additional Measles Cases reported in Oklahoma
On Mar. 25, 2025, the Oklahoma State Department of Health (OSDH) reported that nine additional measles cases had…
-
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
On Mar. 14, 2025, Sanofi announced the immediate adoption of influenza strains selected by the U.S. Food and…
-
U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
On Mar. 9, 2025, Celltrion announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and…
-
Pfizer Plans to Invest $1 Billion in China
On Nov. 8, 2024, as companies begin considering moving their manufacturing operations outside of China in order to…
-
Biotechnology | Diagnostics | FDA | Neurology | Therapeutics
FDA Approved Drug with New Mechanism of Action for Treatment of Schizophrenia
On Sept. 26, 2024, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb’s Cobenfy (xanomeline and trospium…
-
international team of scientists announced mapping complete genetic makeup of Lyme disease-causing bacteria
On Aug. 14, 2024, an international team of scientists announced they had sequenced the complete genomes of the…
